Glaxo Wellcome UK
Part of GSK
Company
Glaxo Wellcome UK develops 3 assets, the furthest in phase 3, no development reported (sotrovimab in COVID-19). Mostly antibody acting on S.
- 3
- Assets
- Furthest stage
- Phase 3, no development reported
- 0
- Trials
- 0
- Signals
Pipeline
3Monoclonal antibody engineered for immune engagement.
Phase 3, no development reported, Antibody, S, COVID-19, Partner
Neutralizes influenza A viruses by binding the conserved stem region of viral hemagglutinin.
Phase 2, discontinued, Antibody, influenza A, influenza a prevention (Phase 1), Partner
Binds SARS-CoV-2 spike protein to neutralize the virus, with an engineered Fc region enhancing immune effector functions.
Preclinical, no development reported, Antibody, COVID-19, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Deals1
- Signals5
- Similar companies6